NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SLRN

Acelyrin Inc

Apr 28 • 02:30PM ET

2.18

Dollar change +0.01
Percentage change 0.69	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN MRNA BIIB AMGN ALNY GILD INCY BMRN NBIX

| Held by: VTI IWM VXF IWN IBB VTWO SCHA VHT IWC AVSC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	27.51%	Shs Outstand	100.45M	Perf Week	-4.17%
Market Cap	220.48M	Forward P/E	-	EPS next Y	-1.33	Insider Trans	-0.09%	Shs Float	73.15M	Perf Month	-17.23%
Income	-248.23M	PEG	-	EPS next Q	-	Inst Own	75.92%	Short Float	5.05%	Perf Quarter	11.48%
Sales	0.00M	P/S	-	EPS this Y	40.53%	Inst Trans	5.46%	Short Ratio	1.93	Perf Half Y	-64.53%
Book/sh	4.56	P/B	0.48	EPS next Y	15.29%	ROA	-40.24%	Short Interest	3.69M	Perf Year	-52.19%
Cash/sh	4.44	P/C	0.49	EPS next 5Y	-	ROE	-44.54%	52W Range	1.85 - 7.25	Perf YTD	-30.41%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-53.43%	52W High	-69.86%	Beta	1.17
Dividend TTM	-	Quick Ratio	18.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.43%	ATR (14)	0.16
Dividend Ex-Date	-	Current Ratio	18.10	EPS Y/Y TTM	36.27%	Oper. Margin	-	RSI (14)	41.74	Volatility	7.12% 7.71%
Employees	83	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	8.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	18.77%	Payout	-	Rel Volume	0.11	Prev Close	2.17
Sales Surprise	-	EPS Surprise	-19.34%	Sales Q/Q	-	Earnings	Mar 27	Avg Volume	1.91M	Price	2.18
SMA20	-4.75%	SMA50	-11.46%	SMA200	-45.02%	Trades		Volume	161,432	Change	0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$18 → $6
Jul-08-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$13
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Apr-21-25 06:30AM	Alumis and ACELYRIN Announce Amended Merger Agreement (GlobeNewswire)
Apr-04-25 04:34PM	Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger (GlobeNewswire) -5.81%
Apr-03-25 12:22PM	Pliant Therapeutics: An Activist On Deck (Seeking Alpha) -5.84%
Mar-18-25 04:46AM	Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-14-25 07:57AM	Makary advances to full senate vote; Acelyrin, Pliant adopt poison pills (BioPharma Dive)
07:00AM	Loading…
Mar-13-25 07:00AM	ACELYRIN Adopts Limited-Duration Stockholder Rights Plan (GlobeNewswire)
Mar-07-25 09:57AM	Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now? (Insider Monkey)
Mar-04-25 09:01AM	Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire) -7.06%
09:01AM	ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger (GlobeNewswire)
09:00AM	ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger (GlobeNewswire)
06:25AM	Neumora bids farewell to R&D head; Biohavens one step forward, one step back data (BioPharma Dive)
Feb-21-25 06:24AM	Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMAs new chair (BioPharma Dive) +19.82%
Feb-20-25 09:00PM	ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences (GlobeNewswire)
Feb-06-25 04:15PM	Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases (GlobeNewswire) +7.37%
Jan-06-25 04:00PM	ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease (GlobeNewswire) -8.64% -36.96%
08:00PM	Loading…
Jan-02-25 08:00PM	ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab (GlobeNewswire) +5.10% +15.76%
Dec-10-24 04:30PM	ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis (GlobeNewswire) -5.36% -16.01%
Nov-14-24 02:17AM	Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ... (GuruFocus.com) -13.71%
Nov-13-24 04:00PM	ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-24 04:00PM	ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024 (GlobeNewswire)
Oct-16-24 07:00AM	ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease (GlobeNewswire) +6.29%
Sep-19-24 07:00AM	ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024 (GlobeNewswire) +15.22%
Sep-12-24 01:30AM	Significant Acquisition by T. Rowe Price Investment Management in Acelyrin Inc (GuruFocus.com)
Sep-10-24 07:00AM	ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery (GlobeNewswire)
Aug-22-24 07:00AM	ACELYRIN, INC. to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.42%
Aug-13-24 04:00PM	ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results (GlobeNewswire) -14.71%
03:37AM	Why Is Acelyrin, Inc. (SLRN) The Best New Penny Stock to Buy Now? (Insider Monkey)
Aug-06-24 04:30PM	ACELYRIN, INC. to Report Second Quarter 2024 Financial Results and Corporate Update on August 13, 2024 (GlobeNewswire)
Jun-05-24 07:00AM	ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024 (GlobeNewswire)
May-29-24 07:00AM	ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024 (GlobeNewswire)
11:54AM	Loading…
May-15-24 11:54AM	SLRN Stock Earnings: Acelyrin Beats EPS for Q1 2024 (InvestorPlace)
May-09-24 08:01AM	ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Leadership Transition (GlobeNewswire)
Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire) +10.89%
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire) +8.51%
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41% +8.16%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com) -8.70%
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire) -10.36%
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire) -54.12%
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kim Mina	Chief Executive Officer	Mar 17 '25	Sale	2.74	17,986	49,354	671,753	Mar 19 06:11 PM
Murugan Amar	Chief Legal Officer	Mar 17 '25	Sale	2.74	3,913	10,737	121,587	Mar 19 06:06 PM
Mpofu Shephard	Chief Medical Officer	Mar 17 '25	Sale	2.74	3,211	8,811	121,789	Mar 19 05:55 PM
Kim Mina	Officer	Mar 17 '25	Proposed Sale	2.75	18,052	49,643		Mar 14 09:04 PM
Becker Daniel J.	Director	Jul 17 '24	Sale	6.86	1	7	2,999	Jul 19 06:18 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLRN

Acelyrin Inc

Upgrade your FINVIZ experience